Superfluid Dx, Inc.

Superfluid’s platform technology is applicable to a wide variety of diseases. We are currently focused on Alzheimer’s Disease, where there are urgent medical needs. This minimally invasive approach eliminates the need for spinal taps and expensive, inaccurate brain scans. It allows repeat assessment of a patient’s disease state over time. It is evident that “liquid biopsy” holds advantages over a tissue biopsy in providing minimally invasive follow-up of patients in the clinical setting.